Duisburg

• Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence Ended recruitment
  2024-511832-29-00 4 2020-08-05 High risk adenocarcinoma of the prostate after radical prostatectomy (
• CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi … Ended recruitment
  2023-509089-39-00 5 2020-07-01 Non-Muscle Invasive Bladder Cancer
• A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment
  2024-513464-26-00 5 2018-10-18 Multiple Myeloma
• Study to evaluate the efficacy and safety of Durvalumab(MEDI4736) in combination with intravesical BCG for the treatment of patients diagnos … Ended recruitment
  2023-505341-23-00 5 2018-07-27 Non-muscle invasive bladder cancer
• Trial on efficacy and safety of vaccination of newly diagnosed glioblastoma patients with the patient's own immune cells. Ended recruitment
  2024-514820-18-00 4 2018-03-07 newly diagnosed glioblastoma
• A prospective, randomised, multi-centre, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges … Halted
  2025-521764-35-01 5 2026-01-27 acute pharyngitis
• A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and … Halted
  2022-502903-31-00 5 2025-11-05 Patients with ADHD (according to ICD-10 / DSM-5)
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub … Ended
  2024-515717-17-00 5 2024-10-28 birch pollen-induced allergic rhinitis birch pollen-induced allergic r
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane … Ended
  2023-504942-75-01 5 2024-08-22 Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or witho
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 5 2023-11-02 Chronic pain due to diabetic polyneuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended
  2022-500898-13-00 5 2023-11-02 Chronic Pain due to traumatic or post-operative peripheral Neuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended
  2022-500899-66-00 5 2023-11-02 Chronic pain due to central Neuropathy of any Genesis
• Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended
  2022-502151-54-00 5 2023-11-02 Chronic back pain
• A study to find out if daridorexant is safe and efficacious to treat insomnia in patients with insomnia and comorbid nocturia Ended
  2022-501246-30-00 6 2023-03-08 Insomnia Disorder
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 6 2022-04-08 Hypercholesterolemia
• A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents … Ended
  2024-513304-33-00 5 2022-03-17 Type 1 diabetes mellitus
• VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended
  2023-509233-39-00 4 2022-01-20 Moderately to Severely Active Ulcerative Colitis
• Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended
  2022-502040-13-00 4 High-risk Myelodysplastic neoplasia

Showing 49–70 of 70 trials